Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination
PR97312
PHILADELPHIA and FLORENCE, Italy, August 2, 2022 /PRNewswire=KYODO JBN/ --
Preclinical data support the potential of ONA-XR plus estrogen receptor
degraders in endocrine resistant disease models
Context to initiate Phase 1b/2 clinical trial in Q4 2022
Context Therapeutics Inc. ("Context" or the "Company") (Nasdaq: CNTX), a
women's oncology company developing small molecule and immunotherapy treatments
for breast and gynecological cancers, and The Menarini Group ("Menarini") today
announced a clinical trial collaboration and supply agreement for Menarini's
oral selective estrogen receptor degrader (SERD), elacestrant.
This agreement will support the upcoming Phase 1b/2 ELONA clinical
proof-of-concept trial evaluating onapristone extended release (ONA-XR), an
oral progesterone receptor (PR) antagonist, in combination with elacestrant in
estrogen receptor positive (ER+), PR+ HER2- metastatic breast cancer (mBC)
patients who have previously been treated with a CDK4/6 inhibitor. Context will
sponsor the clinical trial and Menarini will supply elacestrant at no cost.
According to the American Cancer Society, breast cancer is the second most
common cancer among women occurring in 1 in 8 women (13%) over the course of a
woman's lifetime, with ~280,000 new cases of invasive breast cancer and 51,400
cases of non-invasive breast cancer expected in 2022. Elacestrant is the first
oral SERD to demonstrate
[https://www.menarini.com/en-us/news/news-detail/positive-emerald-trial-results-
for-elacestrant-presented-at-san-antonio-breast-cancer-symposium-2021 ] a
statistically significant and clinically meaningful improvement in
progression-free survival (PFS) versus standard-of-care (SOC) endocrine therapy
in a Phase 3 trial in patients with ER+, HER2- mBC, with 30% reduction in the
risk of progression or death in all patients. Data also showed that 22% of
patients were alive and progression-free at 12 months after elacestrant
treatment initiation vs. 9% with SOC in the overall population. Therefore,
elacestrant may become the new backbone endocrine therapy for ER+, HER2- mBC.
Preliminary data from preclinical studies suggest that a dual ER and PR
blockade may be associated with enhanced tumor control. The ELONA clinical
trial will be evaluating this important hypothesis.
"We are grateful to Menarini for their collaboration as we explore the
therapeutic potential of adding ONA-XR, our oral PR antagonist, to
elacestrant," said Tarek Sahmoud, MBBCh, Ph.D., Context's Chief Medical
Officer. "We hope that this combination will further improve the clinical
outcome in patients with ER+, PR+, HER2- mBC."
"ONA-XR's ability to restore hormone sensitivity and its tolerability profile
positions it well for combination with elacestrant," said Nassir Habboubi,
M.D., Menarini's Global Head of R&D.
Context anticipates initiating the Phase 1b/2 clinical trial in the fourth
quarter of 2022. The two companies will form a joint committee to review
results.
About Menarini Group
The Menarini Group is a leading international pharmaceutical and diagnostics
company, with a turnover of over $4 billion and over 17,000 employees. Menarini
is focused on therapeutic areas with high unmet needs with products for
oncology, cardiology, pneumology, gastroenterology, infectious diseases,
diabetology, inflammation, and analgesia. With 18 production sites and 9
Research and Development centers, Menarini's products are available in 140
countries worldwide. For further information, please visit www.menarini.com.
About ONA-XR
ONA-XR (onapristone extended release) is a potent and specific antagonist of
the progesterone receptor (PR) that is orally administered. Currently, there
are no approved therapies that selectively target PR+ cancers. Preliminary
preclinical and clinical data suggest that ONA-XR has anticancer activity by
inhibiting progesterone receptor binding to chromatin, downregulating cancer
stem cell mobilization and blocking immune evasion. ONA-XR is currently being
evaluated in three Phase 2 clinical trials and one Phase 1b/2 clinical trial in
PR+ breast, ovarian and endometrial cancers. ONA-XR is an investigational drug
that has not been approved for marketing by any regulatory authority.
About Context Therapeutics® Context Therapeutics Inc. (Nasdaq: CNTX), is a
women's oncology company developing small molecule and immunotherapy treatments
to transform care for breast and gynecological cancers. The Company's robust
clinical program for lead candidate onapristone extended release (ONA-XR)
comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in
hormone-driven breast, ovarian, and endometrial cancer. ONA-XR is a novel,
first-in-class small molecule under development as a potent and specific
antagonist of the progesterone receptor, a key unchecked mechanism in
hormone-driven women's cancers. Context is headquartered in Philadelphia, PA.
For more information, visit www.contexttherapeutics.com.
Forward-looking Statements
This press release contains "forward-looking statements" that involve
substantial risks and uncertainties for purposes of the safe harbor provided by
the Private Securities Litigation Reform Act of 1995. Any statements, other
than statements of historical fact, included in this press release regarding
strategy, future operations, prospects, plans and objectives of management,
including words such as "may," "will," "expect," "anticipate," "plan,"
"intend," and similar expressions (as well as other words or expressions
referencing future events, conditions, or circumstances) are forward-looking
statements. These include, without limitation, statements regarding (i) the
timing to initiate, enroll, and obtain initial data for our clinical trials,
(ii) the results of our clinical trials, (iii) the potential benefits of the
product candidates, (iv) the likelihood data will support future development,
and (v) the likelihood of obtaining regulatory approval of the product
candidates. Forward-looking statements in this release involve substantial
risks and uncertainties that could cause actual results to differ materially
from those expressed or implied by the forward-looking statements, and we,
therefore cannot assure you that our plans, intentions, expectations, or
strategies will be attained or achieved. Other factors that may cause actual
results to differ from those expressed or implied in the forward-looking
statements in this press release are discussed in our filings with the U.S.
Securities and Exchange Commission, including the section titled "Risk Factors"
contained therein. Except as otherwise required by law, we disclaim any
intention or obligation to update or revise any forward-looking statements,
which speak only as of the date they were made, whether as a result of new
information, future events or circumstances or otherwise.
Logo - https://mma.prnewswire.com/media/652491/MENARINI_Group_Logo.jpg
SOURCE: Menarini Industrie Farmaceutiche Riunite
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。